

phencyclidine-treated mice via its sigma-1 agonistic activity (Hashimoto et al., 2007). Therefore, one of the possible explanations for the improvement of cognitive impairments in the present case may be the sigma-1 agonism of fluvoxamine, rather than the antidepressant effects of serotonin reuptake inhibition, although there are still many other possibilities as well, including modulation of the GABA system (Chertkow et al., 2006). Nonetheless, our results suggest that sigma-1 receptor agonists, including fluvoxamine, may be one of the candidates for treating cognitive impairments in schizophrenia.

#### 4. Conclusion

We reported here a female case of schizophrenia with cognitive impairments. The cognitive impairments were dramatically improved with adjunctive treatment of fluvoxamine added to risperidone, possibly due to the potent sigma-1 receptor agonism of fluvoxamine.

#### References

- Chertkow Y, Weinreb O, Youdim MB, Silver H. The effect of chronic co-administration of fluvoxamine and haloperidol compared to clozapine on the GABA system in the rat frontal cortex. *Int J Neuropsychopharmacol* 2006;9:287-96.
- Ginsberg DL, Schooler NR, Buckley PF, Weiden PJ. Optimizing treatment of schizophrenia: enhancing affective/cognitive and depressive functioning. *CNS Spectr* 2005;10(suppl 1):1-15.
- Hughes H, Kumari V, Soni W, Das M, Binneman B, Drozd S, O'Neil S, Mathew V, Sharma T. Longitudinal study of symptoms and cognitive function in chronic schizophrenia. *Schizophr Res* 2003;59:137-46.
- Harvey PD, Bowie CR, Friedman JI. Cognition in schizophrenia. *Curr Psychiatry Rep* 2001;3:423-8.
- Hashimoto K, Fujita Y, Iyo M. Phencyclidine-induced cognitive deficits in mice are improved by subsequent subchronic administration of fluvoxamine: role of sigma-1 receptors. *Neuropsychopharmacology* 2007;32:514-21.
- Lehman AF, Carpenter Jr WT, Goldman HH, Steinwachs DM. Treatment outcomes in schizophrenia: implications for practice, policy, and research. *Schizophr Bull* 1995;21:669-75.
- Narita N, Hashimoto K, Tomitaka S, Minabe Y. Interactions of selective serotonin reuptake inhibitors with subtypes of sigma receptors in rat brain. *Eur J Pharmacol* 1996;307:117-9.
- Silver H. Selective serotonin re-uptake inhibitor augmentation in the treatment of negative symptoms of schizophrenia. *Expert Opin Pharmacother* 2004;5:2053-8.

Masaomi Iyo\*

Yukihiko Shirayama

Hiroyuki Watanabe

Mihisa Fujisaki

Ryosuke Miyatake

Goro Fukami

Akihiro Shiina

Michiko Nakazato

Tetsuya Shiraishi

Department of Psychiatry, Graduate School of Medicine,

Chiba University, Japan

E-mail address: iyo@faculty.chiba-u.jp (M. Iyo).

\*Corresponding author. Department of Psychiatry,  
Graduate School of Medicine, Chiba University, 1-8-1 Inohana,  
Chuo-ku, Chiba City 260-8670, Japan.  
Tel.: +81 43 226 2146; fax: +81 43 226 2150.

Masaomi Iyo

Kenji Hashimoto

Division of Clinical Neurosciences,

Center for Forensic Mental Health, Chiba University, Japan

Tsuyoshi Ookami

Kikyo Hospital, Japan

25 October 2007